Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-001209-26
    Sponsor's Protocol Code Number:01032012
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2013-09-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2012-001209-26
    A.3Full title of the trial
    Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.
    Wirksamkeit von Tranylcypromin (TCP) in Aufdosierung bis 60mg und Lithiumaugmentation (Li.-Aug.) von Antidepressiva in der Akuttherapie der therapieresistenten unipolaren Depression. Eine offene randomisierte Studie im zweistufigen Simon-Phase - II – Design.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and the combination of lithium and antidepressants (Li.-Aug.) in the acute treatmet of therapy-resistant Depression. In this study the assignment to the treatment groups (TCP or Li.-Aug.) is made by chance. Physicians and participants know which treatment is applicated. If a planned interim-analysis reveals no superiority of TCP the study will be terminated previously.
    Wirksamkeit von Tranylcypromin (TCP) (bis 60mg/Tag) und der Kombination von Lithium und Antidepressiva (Li.-Aug.) in der Behandlung der unipolaren Depression. Die Zuordnung zu den Behandlungsgruppen (TCP oder Li.-Aug.) erfolgt zufällig wobei Arzt und Patient über diese Zuordnung informiert sind. Die Studie wird vorzeitig beendet, wenn sich in einer geplanten Zwischenauswertung keine Überlegenheit von TCP zeigt.
    A.3.2Name or abbreviated title of the trial where available
    TraveL-Study (Tranylcypromin vs. Lithiumaugmentation)
    TraveL-Studie (Tranylcypromin vs. Lithiumaugmentation)
    A.4.1Sponsor's protocol code number01032012
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCharité Universitätsmedizin Berlin
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportARISTO Pharma GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCharité Universitätsmedizin Berlin
    B.5.2Functional name of contact pointKlinik für Psychiatrie (CCM)
    B.5.3 Address:
    B.5.3.1Street AddressCharitéplatz 1
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code10117
    B.5.3.4CountryGermany
    B.5.4Telephone number004930450517296
    B.5.5Fax number004930450517944
    B.5.6E-mailroland.ricken@charite.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Jatrosom N (10 and 20mg Tablets will be used in the trial)
    D.2.1.1.2Name of the Marketing Authorisation holderARISTO Pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameJatrosom N
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Quilonum retard
    D.2.1.1.2Name of the Marketing Authorisation holderTeofarma S.r.l.
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameQuilonum retard
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Major Depression
    ICD10: F 32.1, F 32.2, F32.3, F33.1, F33.2, F33.3
    Klassifikationscode MedDRA : 10012378
    unipolare Depression
    Klassifikationscodes ICD10: F 32.1, F 32.2, F32.3, F33.1, F33.2, F33.3
    Klassifikationscode MedDRA : 10012378
    E.1.1.1Medical condition in easily understood language
    Depression (Major Depression; unipolar Depression; depressive episode that does not occour in bipoar disorder or is not induced by substance dependency or somatic disease)
    Depression; depressive Episode, die nicht im Rahmen einer bipolaren Störung, organischen psychischen Störung oder substanzinduzierten (z.B. bei Drogenabhängigkeit) psychischen Störung auftritt
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Mental Disorders [F03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10057840
    E.1.2Term Major depression
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary aim of the study is to investigate the efficacy of a six-week Treatment with Tranylcypromine (TCP) in doses up to 60mg / day in therapy-resistant unipolar Depression. Evaluation of efficacy is made by comparison with a historical control group of patients receiving lithiumaugmentation taken from the metaanalysis of Bauer et al., 2007 describing a response rate of 42%. In our study the validity of these metaanalytic lithium-response-data will be controlled by a Group of participants receiving lithiumaugmentation. The randomisation-ratio of TCP : Li.Aug. is 3 : 1. This is an open label randomized, multicentre prospective clinical trial in a Simon-Phase-II-design. If a planned Interim-Analysis does not reveal superiority of TCP over Li.-Aug. the study will be terminated previously.
    Primäres Ziel ist die Prüfung der Wirksamkeit einer sechswöchigen Behandlung mit Tranylcypromin (TCP) in Aufdosierung bis 60mg in der Akuttherapie der therapieresistenten unipolaren Depression. Die Beurteilung der Wirksamkeit erfolgt anhand eines Vergleiches mit historischen Kontrollen zur Wirksamkeit der Lithiumaugmentation aus der Metaanalyse Bauer et al. 2007, die für die Lithiumaugmentation von Antidepressiva als Referenztherapie eine Responserate von 42% beschreibt. Diese metaanalytischen Response-Raten zur Li.-Aug. werden durch die im Rahmen der Studie rekrutierte Gruppe von Patienten die eine Li.-Aug. erhalten überprüft. Das Randomisierungsverhältnis von TCP zu Li.-Aug. beträgt 3 zu 1.
    Es handelt sich um eine offene, randomisierte prospektive, multizentrische Studie in einem zweistufigen Simon-Phase- II – Design. Ergeben sich in einer geplanten Zwischenauswertung keine Hinweise auf eine Überlegenheit von TCP wird die Studie vorzeitig abgebrochen.
    E.2.2Secondary objectives of the trial
    Investigation of efficacy (other than Response), tolerability, patients`s satisfaction, qulaity of life, fisibility, sexual dysfunction, body-weight, treatment-effort in patients treated with TCP or Li.-Aug.
    Erfassung der Wirksamkeit (andere Parameter als Response), Verträglichkeit, Patientenzufriedenheit, Lebensqualität, Praktikabilität, sexuelle Dysfunktion, Verlauf des Körpergewichtes und Therapieaufwand unter Therapie mit Tranylcypromin und der Lithiumaugmentation von Antidepressiva.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Furthermore the following explorative investigations are planned to be conducted:
    1) Pharmacokinetics of TCP by measuring Serum Levels in patients receiving doses of 40mg or higher
    2) Investigation of HPA-axis reagibility using the Cortisol Awakening Response (CAR) in patients before and during treatment with Li.-Aug. or TCP
    3) Investigation of Serum and Plasma Brain Derived Neurotrophic factor (BDNF) and neurothrophins and their relation to clinical varaiables in patients treated with Li.-Aug. or TCP
    4) Investigation of immunological serum parameters (IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17,Interleukin, IFN-gamma, TNF-alpha) and the relation to clinical variables in patients before and during Treatment with Li.-Aug. or TCP
    5) Investigation of Ghrelin, Leptin and Leptinreceptor and the relation to clinical variables (weight gain) in patients before and during Treatment with Li.-Aug. or TCP
    6) pharmacogenetic Investigation on response and side-effect prediction
    7) Investigation of the relation between childhood Trauma, clinical varaibles (treatment-response) and the biological parameters mentioned above in patients before and during treatment with Li.-Aug. or TCP
    8) in a subgroup of patinets (n=40) before and during Treatment with TCP and Li.-Aug. and in healthy controls (n=20; healthy controls do not receive medication!) the responsivity of the dopaminergic mesolimbic reward system and the processing of emotions in the amygdala will be investigated using functional megnetic resonance tomography (fMRT).
    Weiterhin werden explorative Untersuchungen im Rahmen eines wissenschaftlichen Begleitprogramms durchgeführt:
    1) Untersuchung der Pharmakokinetik von TCP (ab 40mg Tagesdosis)
    2) Untersuchung des HPA-Systems vor und unter Therapie mit TCP / Li-Aug. mittels Cortisol Awakening Response (CAR) und Analyse des Zusammenhanges mit klinischen Variablen.
    3) Untersuchung des Verlaufes von Serum und Plasma Brain Derived Neurotrophic factor (BDNF) vor und unter TCP / Li.-Aug. und Analyse des Zusammenhanges mit klinischen Variablen.
    4) Untersuchung des Verlaufes immunologischer Parameter (IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17,Interleukin, IFN-gamma, TNF-alpha) vor und unter TCP / Li.-Aug. und Analyse des Zusammenhanges mit klinischen Variablen.
    5) Untersuchung des Verlaufes hormoneller Parameter, die die Appetit- und Gewichtsregulation beeinflussen (Ghrelin, Leptin, Leptinrezeptor) vor und unter TCP / Li.-Aug. und Analyse des Zusam-menhanges mit klinischen Variablen.
    6) pharmakogenetische Untersuchungen zur Response- und Nebenwirkungsprädiktion.
    7) Untersuchung des Zusammenhanges traumatischer Kindheitserlebnisse auf den Krankheitsverlauf, den Verlauf der antidepressiven Therapie und die genannten biologischen Parameter.
    8) bei einer Subgruppe der Studienteilnehmer (n=40) und an gesunden Probanden (n=20) wird die Responsivität des dopaminergen mesolimbischen Belohnungssystems vor und nach antidepressiver Therapie mit TCP und Li.-Aug mittels funktioneller Kernspintomographie (fMRT) untersucht.
    E.3Principal inclusion criteria
    • Major Depression
    • Indication for antidepressiv pharmakotherapy
    • current in- or outpatient status
    • insufficient response to a Minimum of one adequate Treatment-attempt with an antidepressant (Minimum dursation of 4 weeks, adequate dose according to product Information)
    • at baseline MADRS > 20 or MADRS > 16 with no Amelioration in the last 4 weeks
    • written informed consent after verbal and written information
    • Age: 18 years or higher
    • negative pregnancy test
    • Infertility or highly effective method of contraception (PEARL - Index < 1%)
    • Patient fulfills one or of the following more criteria: a) females with no child bearing potential (e. g. after hysterektomia, bilateral oophorektomia, bilateral tubenligatur, Menopause for ≥ 2 Jahre; b) females with child bearing potential and generative males using a highly effective method of contraception (defined as Pearl-Index < 1): sexual abstinence, intrauterine Contarception-method, oral contraceptive, hormone-spiral, hormone-implantation, Transdermal-patch, combination of two barriermethods, partner is sterile (without child bearing potential) and the only partner of the study-patricipant
    • patient`s ability to consent certified by a physician
    • written informed consent (accordig to AMG §40 (1) 3b)
    • no participation in another clinical Trial (according to AMG)one month before and during individual study Duration

    • unipolare Major Depression
    • Indikation für eine antidepressive Pharmakotherapie
    • aktuell stationär oder ambulant Behandlung
    • unzureichendes Ansprechen auf mindestens einen adäquaten antidepressiven Behandlungsversuch (mindestens 4 Wochen in ausreichender Dosierung gem. Fachinfo)
    • bei Studieneintritt MADRS > 20 oder MADRS > 16 und zuletzt länger als 4 Wochen keine Besserung
    • schriftliche Patienteneinwilligung nach mündlicher und schriftlicher Aufklärung
    • Mindestalter: 18 Jahre
    • negativer Schwangerschaftstest
    • Unfruchtbarkeit oder eine hocheffektive Methode der Schwanger¬schafts¬verhütung (PEARL - Index < 1%)
    • Erfüllung eines oder mehrerer der folgenden Kriterien:
    • Nicht-gebärfähige weibliche Studienteilnehmerin: z. B. nach Hysterektomie, bilateraler Oophorektomie, bilateraler Tubenligatur, Menopause seit ≥ 2 Jahre
    • gebärfähige Frauen und zeugungsfähige Männer unter hocheffektiver Kontrazeption (definiert als Pearl-Index < 1): Enthaltsamkeit, Intrauterine Ver¬hütungs¬methode, Pille, Hormonspirale, Hormonimplantat, Transdermalpflaster, Kombination zweier Barrieremethoden, Partner ist steril und der einzige Partner des Studienteilnehmers
    • ärztlich bestätigte Einwilligungsfähigkeit
    • schriftliches Einverständnis (laut AMG §40 (1) 3b)
    • keine Teilnahme an einer anderen AMG-Studie (1 Monat vor) und während der Studienteilnahme
    E.4Principal exclusion criteria
    • Contraindikationen against TCP, Lithium or the antidepressant thet the patient received prior to study entry (see product informations for list of contraindications). A contraindication to tranylcypromine is, for example, insufficiently adjusted or adjustable arterial hypertension.
    • Pretreatment with Li.-Aug., TCP, elektroconvulsivetherapy (ECT) in current depressive episode
    • severe somatic illness with corresponding polypharmacy
    • Pregnancy, breast-feednig
    • age > 75 years
    • women with child-bearing potential and men in reproductive age without using of a highly effective contraception method (PEARL-Index < 1%)
    • laboratory and / or ECG Findings, that exclude treatment with lithium
    • depressive Syndrom due to a non-psychiatric condition or secondary due to another axis-I-diagnosis
    • Diagnosis of antisocial personality disorder, a profound personality disorder, schizophrenia, severe anxiety- or panic-disorder
    • Diagnosis of dementia or an organic brain-disease
    • Diagnosis of substance dependency and use of the substance in the last six months (coffein and Nicotin allowed)
    • psychiatric hospitalisation by law (according to AMG §40 (1) 4)
    • Kontraindikationen gegen TCP, Lithium, oder das verordnete Antidepressivum– für Liste der Kontraindikationen siehe Fachinformation. Eine Kontraindikation gegen Tranylcypromin ist z.B. eine nicht suffizient eingestellte oder einstellbare arterielle Hypertonie.
    • Vorbehandlung mit Li.-Aug., TCP, Elektokonvulsionstherapie (EKT) in der aktuellen Phase
    • schwere somatische Erkrankungen mit entsprechender Polypharmazie
    • Schwangerschaft, Stillzeit
    • Alter > 75 Jahre
    • Frauen im gebärfähigen Alter und Männer im zeugungs¬fähigen Alter ohne Anwendung einer hocheffektiven Schwangerschaftsverhütungsmethode (PEARL-Index < 1%)
    • Laborwerte u./o. EKG Befunde, die gegen eine Lithiumeinnahme sprechen
    • depressives Syndrom aufgrund einer nicht-psychiatrischen bzw. im Rahmen einer weiteren Achse-I-Diagnose
    • Diagnose einer antisozialen Persönlichkeitsstörung, höhergradigen/schweren Persönlichkeitsstörungen, Schizophrenien, schweren Angst- und Panikstörung
    • Diagnose einer Demenz oder einer organischen Gehirnerkrankung
    • Diagnose einer Substanzabhängigkeit und in den letzten 6 Monaten Konsum der Substanz (ausgenommen Coffein und Nikotin)
    • Unterbringung in einer Anstalt auf gerichtliche oder behördliche Anordnung (laut AMG §40 (1) 4)
    E.5 End points
    E.5.1Primary end point(s)
    • Responserate
    Response is defined as 50% Scorereduktion from Baseline or MADRS (Montgomery Asberg Depression Rating Scale) - score ≤12
    • Responserate
    Response ist definiert als 50% Scorereduktion von Baseline oder Wert ≤12 auf der MADRS-Skala (Montgomery Asberg Depression Rating Scale)
    E.5.1.1Timepoint(s) of evaluation of this end point
    weekly assessments
    wöchentlich
    E.5.2Secondary end point(s)
    • Remission-rate - Remission is defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12, Hamilton Depression Rating Scale (HAMD-17) < 7
    • score-changes in MADRS, HAMD-17, Clinical Global Impression (CGI), BDI-II (Beck Depression Inventory Version 2), Inventory of Depressive Symptoms (IDS)
    • time to Remission and Response
    • tolerability and safety measured by the self-rating Antidepressant Side Effect Scale (ASEC) und physicians Adverse Event Report, the percentage of drop-outs, peripheral blood pressure, Laboratory and ECG-findings
    • treatment satisfaction is measured by Treatment Satisfaction Questionaire (TSQ)
    • Quality of life is measured by the Quality of Life Questionaire (QLESQ)
    • Sexual Dysfunktion is measured by the Arizona Sexual Functioning Questionaire (ASEX)
    • Body-weiht is measured by Body weight in KG and Body Maß Index (BMI)
    • treatment Fisibility is measured by the estimated time spent on Treatment and the estimated subjective effort rated by physicians, nurses and patients (on a six step Likert scale)
    • for exploratory Analysis the complete medication is assessed
    Sekundäre Zielparameter und -größen:
    • Remissionsrate (Remission ist definiert als MADRS < 12, HAMD-17 < 7)
    • Veränderungen im MADRS, HAMD-17, CGI, BDI-II, IDS- Wert zur Effektivitätsmessung in den Behandlungsgruppen
    • Zeit bis zur Remission und Response (im Rahmen einer Survival Analyse)
    • Verträglichkeit Sicherheit mittels Selbstbeurteilung (ASEC) und Fremdbeurteilung (Adverse Event Report), Anzahl drop-outs (anteilig), Laboruntersuchungen und EKG-Kontrollen, deutsche Version
    • Therapiezufriedenheit, erfasst mit dem Treatment Satisfaction Questionaire (TSQ), deutsche Version
    • Lebensqualität, erfasst mit dem Quality of Life Questionaire (QLESQ), deutsche Version
    • Sexuelle Dysfunktion, erfasst mit dem Arizona Sexual Functioning Questionaire (ASEX), deutsche Version
    • Gewichtsverlauf, gemessen als Körpergewicht wird in KG und Body Maß Index (BMI)
    • Die Einschätzung des Therapieaufwands (Anwendbarkeit) erfolgt durch Einschätzung der aufgewendeten Zeit durch das Studienpersonal und durch die Erfassung des subjektiv empfundenen Aufwandes durch Arzt, Pflegepersonal und Patienten (auf einer sechsstufigen Likert-Skala)
    • Zur explorativen Analyse wird die Primärmedikation und Komedikation erfasst
    E.5.2.1Timepoint(s) of evaluation of this end point
    a) weekly, starting at baseline: MADRS, HAMD-17, BDI-II, IDS, CGI, peripheral blood pressure (RR), ASEC, Adverse Event Report, asessment of medication
    b)baseline and last visit: ECG, laboratory-findings (according to routine care in the study site), QLESQ, BMI, ASEX
    c) last visit: asessment of Treatment-fisibility
    d) telephone Interview after 3 and 6 month after baseline: HAMD, MADRS, BMI, ASEX
    a) wöchentlich, beginnend bei baseline: MADRS, HAMD-17, BDI-II, IDS, CGI, peripherer Blutdruck (RR), ASEC, Adverse Event Report, Erfassung der Medikation
    b) Baseline und letzte Visite: ECG, Laborbefunde (according to routine care in the study site), QLESQ, BMI, ASEX
    c) letzte Visite: Erfassung der Behandlungsaufwandes
    d) Telefonische Befragung nach 3 und 6 Monaten nach Baseline: HAMD, MADRS, BMI, ASEX
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    exploratory Analysis of:
    - brain-imaging (fMRT) with separate informed consend and Patient information (not conducted)
    - endocrinological (leptin, ghrelin, leptin-receptor, cortisole)
    - neurotrophic factors (BDNF)
    - immunological factors
    explorative Analysen:
    - funktionelle cerebrale Bildgebung
    - endokrine Serumparameter
    - immunologische Serum-Parameter
    - neurotrophe Serumund Plasma-Parameter
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Simon-Phase-II-Design, zweistufig
    two step Simon-phase-II-design
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years11
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 61
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state71
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    keine
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Berlin Research Network on Depression
    G.4.3.4Network Country Germany
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-10-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-05-06
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2024-02-23
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 16:51:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA